95 related articles for article (PubMed ID: 38449660)
1. T cell-mediated tumor killing based signature to predict the prognosis and immunotherapy for glioblastoma.
Liu H; Shi K; Wei Z; Zhang Y; Li J
Heliyon; 2024 May; 10(10):e31207. PubMed ID: 38813229
[TBL] [Abstract][Full Text] [Related]
2. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
Shi T; Gao G
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
[TBL] [Abstract][Full Text] [Related]
3. Bulk anda single-cell transcriptome profiling reveals the molecular characteristics of T cell-mediated tumor killing in pancreatic cancer.
Dai YW; Pan YT; Lin DF; Chen XH; Zhou X; Wang WM
Heliyon; 2024 Mar; 10(5):e27216. PubMed ID: 38449660
[TBL] [Abstract][Full Text] [Related]
4. T Cell-Mediated Tumor Killing-Related Classification of the Immune Microenvironment and Prognosis Prediction of Lung Adenocarcinoma.
Ding P; Liu L; Bin Y; Huang Y; Chen L; Wen L; Zhang R; Tong F; Dong X
J Clin Med; 2022 Dec; 11(23):. PubMed ID: 36498802
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma.
Li J; Yin J; Li W; Wang H; Ni B
Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100
[TBL] [Abstract][Full Text] [Related]
6. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
7. CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma.
Liu K; Li L; Han G
Front Endocrinol (Lausanne); 2023; 14():1226547. PubMed ID: 38333724
[TBL] [Abstract][Full Text] [Related]
8. Characterization of chromatin regulators identified prognosis and heterogeneity in hepatocellular carcinoma.
Dai YW; Chen HB; Pan YT; Lv LX; Wang WM; Chen XH; Zhou X
Front Oncol; 2022; 12():1002781. PubMed ID: 36158697
[TBL] [Abstract][Full Text] [Related]
9. Identification of the molecular subtype and prognostic characteristics of pancreatic cancer based on CD8 + T cell-related genes.
Xu D; Wang Y; Chen Y; Zheng J
Cancer Immunol Immunother; 2023 Mar; 72(3):647-664. PubMed ID: 36036290
[TBL] [Abstract][Full Text] [Related]
10. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.
McCubrey JA; Yang LV; Abrams SL; Steelman LS; Follo MY; Cocco L; Ratti S; Martelli AM; Augello G; Cervello M
Cells; 2022 Jul; 11(14):. PubMed ID: 35883598
[TBL] [Abstract][Full Text] [Related]
11. Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma.
Liu K; Geng Y; Wang L; Xu H; Zou M; Li Y; Zhao Z; Chen T; Xu F; Sun L; Wu S; Gu Y
Mol Oncol; 2022 Aug; 16(16):3034-3051. PubMed ID: 35810469
[TBL] [Abstract][Full Text] [Related]
12. SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment.
Zhang D; Lindstrom A; Kim EJ; Hwang CI; Hall ML; Lin TY; Li Y
Front Oncol; 2022; 12():890154. PubMed ID: 35785187
[TBL] [Abstract][Full Text] [Related]
13. Molecular Characteristics of T Cell-Mediated Tumor Killing in Hepatocellular Carcinoma.
Hong WF; Liu MY; Liang L; Zhang Y; Li ZJ; Han K; Du SS; Chen YJ; Ma LH
Front Immunol; 2022; 13():868480. PubMed ID: 35572523
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
